Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769963 | 0.85 | HSD11B1 (0.62) | CYP19A1CYP17A1ALDH1A1HSD11B1P2RX7 | |
| SCHEMBL3323668 | 0.83 | KMT2A (0.47) | ALDH1A1HSD11B1P2RX7SMN1; SMN2KMT2A | |
| SCHEMBL3321390 | 0.80 | MEN1 (0.47) | CYP19A1CYP17A1ALDH1A1HSD11B1P2RX7 | |
| SCHEMBL1770092 | 0.80 | HSD11B1 (0.52) | CYP19A1CYP17A1ALDH1A1HSD11B1MEN1 | |
| SCHEMBL1770121 | 0.79 | ALDH1A1 (0.43) | CYP19A1CYP17A1ALDH1A1HSD11B1P2RX7 | |
| SCHEMBL3327784 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HSD11B1P2RX7SMN1; SMN2MEN1 | |
| SCHEMBL1769931 | 0.78 | HSD11B1 (0.55) | ALDH1A1HSD11B1P2RX7SMN1; SMN2HTT | |
| SCHEMBL3323248 | 0.77 | HSD11B1 (0.56) | ALDH1A1HSD11B1KMT2A | |
| SCHEMBL12596448 | 0.76 | ALDH1A1 (0.44) | CYP19A1CYP17A1ALDH1A1HSD11B1SMN1; SMN2 | |
| SCHEMBL1770249 | 0.75 | ALDH1A1 (0.40) | CYP19A1CYP17A1ALDH1A1HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | CYP19A1 112/4885CYP17A1 23/4885ALDH1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.